Detalhe da pesquisa
1.
Systematic or Test-Guided Treatment for Tuberculosis in HIV-Infected Adults.
N Engl J Med
; 382(25): 2397-2410, 2020 06 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-32558469
2.
Standardization of an in vitro Model for Evaluating the Bioavailability of Topically Applied Compounds on Damaged Skin: Application to Sunscreen Analysis.
Skin Pharmacol Physiol
; 30(2): 55-65, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28278501
3.
Evidence of Plasmodium falciparum Malaria Multidrug Resistance to Artemisinin and Piperaquine in Western Cambodia: Dihydroartemisinin-Piperaquine Open-Label Multicenter Clinical Assessment.
Antimicrob Agents Chemother
; 59(8): 4719-26, 2015 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-26014949
4.
Plasmodium falciparum dihydroartemisinin-piperaquine failures in Cambodia are associated with mutant K13 parasites presenting high survival rates in novel piperaquine in vitro assays: retrospective and prospective investigations.
BMC Med
; 13: 305, 2015 Dec 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-26695060
5.
Standard dose raltegravir or efavirenz-based antiretroviral treatment for patients co-infected with HIV and tuberculosis (ANRS 12â300 Reflate TB 2): an open-label, non-inferiority, randomised, phase 3 trial.
Lancet Infect Dis
; 21(6): 813-822, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33667406
6.
A surrogate marker of piperaquine-resistant Plasmodium falciparum malaria: a phenotype-genotype association study.
Lancet Infect Dis
; 17(2): 174-183, 2017 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-27818097
7.
Standard dose raltegravir or efavirenz-based antiretroviral treatment for patients co-infected with HIV and tuberculosis (ANRS 12â300 Reflate TB 2): an open-label, non-inferiority, randomised, phase 3 trial
Artigo
em Inglês
| Arca: Repositório institucional da Fiocruz | ID: arc-50476